CDMO partnerships are great when they are successful, but what happens when they falter? The complexity of modern outsourcing partnerships means that failure is often costly, with consequences that can ripple across timelines, budgets, and reputations…

Biopharma companies are increasingly dependent on CDMOs to streamline production, enhance efficiency, and accelerate drug development. As therapies become more complex and regulatory demands grow, the ability to outsource manufacturing to a trusted partner has never been more essential…

Pharmaceutical manufacturing is the backbone of global healthcare, yet its environmental footprint is a growing concern. The sector is responsible for significant greenhouse gas emissions, excessive water consumption, and large-scale hazardous waste production…

India’s pharmaceutical industry has long been synonymous with cost-effective pharmaceutical manufacturing - particularly when it comes to generic drugs. In recent years, India has been making a significant shift from low-cost generic drug production into CDMO services…

The global biologics market is expected to reach USD 720 bn by 2030, fueled by increasing demand for biologics, biosimilars, and advanced therapies. It is undoubtedly an area of keen interest for CDMOs that specialize in biopharmaceutics...

As the demand for advanced therapies continues to grow, CDMOs are fast becoming the solution for biopharma companies that need specialized expertise and capabilities that are scalable for their drug development and commercialization...

The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO market value, which ended the year with a valuation of USD 185 billion…

Overall, 2024 was a good year to be working in the CDMO industry, but will the outlook stay positive for 2025? Forecasts predict a steady rise in continuing growth trends from 2024, with estimates indicating the global pharmaceutical CDMO market is set to grow from USD 184.90 bn in 2024 to USD 197.40 bn in 2025…

The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade, but is it merely a buzzword or does it represent a genuine paradigm shift?

If you were to launch a biopharma startup today, where would you find the skills, talent, and space to bring your vision to life? Biopharma incubators are usually the answer…

Last month, hedge fund Starboard Value acquired a $1 bn stake in Pfizer, at the same time, sharply criticizing the company's management for recent underperformance and strategic missteps…

As the 2024 U.S. election between Donald Trump and Kamala Harris approaches, the biopharma industry is keenly watching how each candidate's policies could shape the future of the sector…

Hurricane Helene was the second major hurricane of the 2024 Atlantic hurricane season as it hit the southeastern United States just two weeks ago. Sadly, over 200 people have already lost their lives, and initial estimates suggest it to be the eighth costliest U.S. hurricane on record…

As 3,000 companies and 60,000 attendees finalize plans before heading to Milan for the 35th anniversary of CPHI, you might have started thinking about what’s on offer and who you are going to catch up with next week…

Celebrating its 35th year, CPHI Milan is expected to attract more than 62,000 biopharma professionals from all over the world, offering unmatched opportunities to connect with global innovators and leaders across the industry…

The first pills date back to roughly 1,500 BC, and whilst the pharmaceutical landscape continues to evolve, drug delivery via oral solid dosage (OSD) remains a dominant form due to the ease with which tablets are administered, patients’ familiarity with the dose form, and efficient manufacturing techniques…

Recently published reports (from The Brainy Insights & InsightAce Analytic Pvt. Ltd) suggest the CDMO industry is poised for significant growth that will continue into the next decade…

Whilst we’re just past the halfway mark of 2024, mid-year analysis of the top selling drugs for the top 10 pharma companies provides some interesting insights into the demands of the market so far this year. Analysis from PharmaVoice shows that the leading drugs have generated over $55bn in revenue so far…

It’s almost impossible for us to compile an edition of The Pharma Navigator without a major update surrounding GLP-1 drugs. Although it is no secret that drugs are generating significant revenue for Big Pharma, is it doing so at the expense of our national healthcare systems?…

A recently published report from Future Market Insights highlights significant potential for global CMO/CDMO market growth; with projections suggesting a significant increase in value from $22.5 bn in 2023 to $39.4 bn by 2033…